Genmab A/S (NASDAQ:GMAB) Hits New 52-Week High – Time to Buy?

Genmab A/S Sponsored ADR (NASDAQ:GMAB) reached a new 52-week high during trading on Wednesday . The stock traded as high as $34.97 and last traded at $34.9120, with a volume of 594683 shares traded. The stock had previously closed at $33.87.

Analyst Ratings Changes

Several equities research analysts have recently commented on GMAB shares. Johnson Rice reaffirmed a “buy” rating on shares of Genmab A/S in a research report on Monday, October 27th. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Guggenheim raised Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 target price on the stock in a report on Tuesday, September 23rd. HC Wainwright lifted their price objective on Genmab A/S from $40.00 to $41.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Finally, Zacks Research downgraded Genmab A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 31st. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $39.75.

Genmab A/S Stock Performance

The company has a market cap of $22.60 billion, a PE ratio of 14.95, a price-to-earnings-growth ratio of 2.15 and a beta of 0.90. The company has a fifty day moving average of $31.61 and a two-hundred day moving average of $28.04.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.65 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The business had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $975.40 million. On average, equities analysts forecast that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of GMAB. Osaic Holdings Inc. grew its position in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after acquiring an additional 440 shares during the last quarter. CWM LLC boosted its stake in shares of Genmab A/S by 50.5% during the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after purchasing an additional 603 shares during the period. NewEdge Advisors LLC grew its holdings in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock worth $38,000 after purchasing an additional 1,143 shares during the last quarter. Brown Brothers Harriman & Co. increased its stake in Genmab A/S by 143.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after buying an additional 780 shares during the period. Finally, AlphaCore Capital LLC purchased a new position in Genmab A/S in the 2nd quarter worth about $44,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.